An update from ConvaTec ( (GB:CTEC) ) is now available.
Convatec reported strong financial results for 2024, with a 6.9% increase in revenue and a 23.7% rise in operating profit. The company’s strategic focus on sustainable growth and innovation has led to double-digit growth in adjusted EPS and cash flow. Convatec’s product launches and pipeline are driving its success, with significant growth across its chronic care categories. The company remains confident in its outlook for 2025, expecting continued organic growth and improved operating margins, supported by productivity improvements and a robust product portfolio.
More about ConvaTec
Convatec is a global medical products and technologies company focused on solutions for managing chronic conditions. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, providing products and services in around 90 countries. Convatec’s offerings aim to improve patient outcomes and reduce care costs, generating over $2 billion in revenue in 2024. The company is part of the FTSE 100 Index.
YTD Price Performance: 11.48%
Average Trading Volume: 4,790,522
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £5.05B
Find detailed analytics on CTEC stock on TipRanks’ Stock Analysis page.